Aveanna Healthcare (NASDAQ:AVAH) Price Target Raised to $11.00

Aveanna Healthcare (NASDAQ:AVAH) had its target price raised by Barclays from $9.00 to $11.00 in a report released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

AVAH has been the subject of several other reports. Raymond James Financial restated an “outperform” rating and set a $13.00 price objective on shares of Aveanna Healthcare in a research report on Friday, December 5th. BMO Capital Markets started coverage on Aveanna Healthcare in a report on Thursday, November 13th. They issued an “outperform” rating and a $11.00 price target for the company. Jefferies Financial Group upped their price objective on Aveanna Healthcare from $11.00 to $12.50 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Truist Financial lifted their price objective on Aveanna Healthcare from $9.50 to $10.00 and gave the stock a “hold” rating in a research report on Friday, November 7th. Finally, Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 20th. Five analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $11.06.

Aveanna Healthcare Trading Down 5.5%

Shares of AVAH stock opened at $9.22 on Friday. The stock has a market cap of $1.93 billion, a P/E ratio of 25.61 and a beta of 2.06. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 140.39. Aveanna Healthcare has a fifty-two week low of $3.67 and a fifty-two week high of $10.32. The business has a fifty day simple moving average of $8.83 and a 200-day simple moving average of $7.80.

Aveanna Healthcare (NASDAQ:AVAH) last issued its quarterly earnings data on Thursday, November 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.08. The firm had revenue of $621.94 million for the quarter, compared to analysts’ expectations of $578.57 million. Aveanna Healthcare had a net margin of 3.29% and a negative return on equity of 143.55%. On average, analysts forecast that Aveanna Healthcare will post -0.06 earnings per share for the current fiscal year.

Insider Activity at Aveanna Healthcare

In other news, major shareholder Paul R. Vigano sold 10,000,000 shares of the stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $9.00, for a total transaction of $90,000,000.00. Following the transaction, the insider directly owned 386,284 shares in the company, valued at $3,476,556. This represents a 96.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jeff Shaner sold 29,357 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $7.85, for a total transaction of $230,452.45. Following the completion of the sale, the chief executive officer owned 2,394,179 shares of the company’s stock, valued at approximately $18,794,305.15. The trade was a 1.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 32,857,606 shares of company stock worth $295,491,307. Corporate insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Aveanna Healthcare

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC raised its holdings in shares of Aveanna Healthcare by 21.2% in the 1st quarter. AQR Capital Management LLC now owns 26,280 shares of the company’s stock worth $142,000 after purchasing an additional 4,602 shares during the period. Goldman Sachs Group Inc. increased its position in Aveanna Healthcare by 8.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 339,853 shares of the company’s stock worth $1,842,000 after purchasing an additional 25,974 shares in the last quarter. Jane Street Group LLC raised its holdings in Aveanna Healthcare by 522.0% in the first quarter. Jane Street Group LLC now owns 75,081 shares of the company’s stock valued at $407,000 after buying an additional 63,010 shares during the period. Strs Ohio acquired a new position in Aveanna Healthcare during the first quarter valued at approximately $218,000. Finally, Rhumbline Advisers grew its stake in Aveanna Healthcare by 4.0% during the first quarter. Rhumbline Advisers now owns 75,581 shares of the company’s stock worth $410,000 after buying an additional 2,918 shares during the period. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.